TCA
NBIX icon

Transcend Capital Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Transcend Capital Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$498K Buy
2,955
+761
+35% +$113K 0.03% 452
2026
Q1 		$289K Sell
2,194
-325
-13% -$43.1K 0.02% 557
2025
Q4 		$357K Buy
2,519
+299
+13% +$43.3K 0.03% 468
2025
Q3 		$312K Buy
+2,220
New +$301K 0.02% 518

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Transcend Capital Advisors's NBIX Position: Q2 2026 in Review

Transcend Capital Advisors increased its Neurocrine Biosciences (NBIX) stake by 35% in Q2 2026, buying an estimated $113K and bringing the position to 2,955 shares worth $498K. The position accounts for 0.03% of the portfolio, ranked #452.

Transcend Capital Advisors first reported a position in NBIX in Q3 2025 and has held it in 4 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Transcend Capital Advisors held 2,955 shares of Neurocrine Biosciences worth $498K as of Q2 2026.
  • Transcend Capital Advisors bought 761 Neurocrine Biosciences shares in Q2 2026, an estimated $113K.
  • Neurocrine Biosciences made up 0.03% of Transcend Capital Advisors's portfolio in Q2 2026, its #452 holding.
  • Transcend Capital Advisors first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 4 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Transcend Capital Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.